Author

B. Kreiswirth

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Gribenko· 1 shared A. Hicks· 1 shared A. S. Anderson· 1 shared A. Schami· 1 shared B. Mathema· 1 shared D. K. Rai· 1 shared E. Titova· 1 shared H. A. Rothan· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. Gribenko

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Drug resistant Mycobacterium tuberculosis strains have altered cell envelope hydrophobicity that influences infection outcomes in human macrophages

A. Schami, M. N. Islam, M. Wall, A. Hicks, R. Meredith, B. Kreiswirth, B. Mathema, J. T. Belisle, J. B. Torrelles

This study examines changes in cell envelope lipids of drug-resistant Mycobacterium tuberculosis strains and their impact on macrophage interactions.

bioRxiv · Apr 10, 2024 · PreprintMicrobiology

Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of Concern

D. K. Rai, I. Yurgelonis, P. McMonagle, H. A. Rothan, L. Hao, A. Gribenko, E. Titova, B. Kreiswirth, K. M. White, Y. Zhu, A. S. Anderson, R. D. Cardin

This paper evaluates the antiviral activity of Nirmatrelvir against multiple SARS-CoV-2 variants using qRT-PCR in VeroE6 cells, showing potent inhibition across all tested variants.

bioRxiv · Jan 17, 2022Microbiology